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ABSTRACT
Objective: This study was designed is to determine the correlation between serum calcium level and serum cartilage oligomeric matrix protein 
(COMP) level in Indonesian patients with rheumatoid arthritis (RA).
Subjects and Methods: The subjects are patients who visit the rheumatology clinic at a government hospital in Bandung, Indonesia. Serum calcium 
level was determined by a complexometric method, and the serum COMP level was determined by enzyme-linked immunosorbent assay. Statistical 
analysis was performed with R software.
Results: The serum calcium level was 82.24±44.82 mg/mL in RA patients and 99.04±60.56 mg/mL in normal controls. The serum COMP level was 
843.80±35.79 ng/ml in RA patients and 830.00±48.92 ng/ml in normal controls.
Conclusion: There is no correlation between serum calcium level and serum COMP levels in RA patients (p=0.967 and rho=0.006).
Keywords: Autoimmune disease, Rheumatoid arthritis monitoring, Complexometric, Enzyme-linked immunosorbent assay, Indonesia.
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease characterized 
by erosive arthritis in the synovial joints on both sides of the body [1]. 
The global prevalence of RA was 0.24%, with no discernible change 
from 1990 to 2010 [2]; the prevalence in Indonesia was 0.1-0.3% in 
2009 [3]. Early diagnosis and treatment of RA are essential to prevent 
joint deformation [4].
In Indonesia, RA diagnoses are based on the clinical manifestations of 
the disease, which are usually observed late in the disease’s progression. 
Therefore, it is necessary to develop a new method for early detection 
of RA. One example of such a method involves the use of cartilage 
oligomeric matrix protein (COMP). This is an extracellular matrix protein 
primarily present in cartilage and it plays a role in the organization of 
collagen fibrils [5] which can used as a potential biomarker to support 
RA diagnosis [6], as RA patients tend to have an increased risk of bone 
loss and fractures [7], due to inactivity of joint function as well as joint 
inflammation [8]. Furthermore, glucocorticoid, which is prescribed 
to RA patients, has been shown to trigger significant bone loss. In this 
study, we measured the correlation of serum calcium levels, which 
represent the level of bone loss, and serum COMP levels in RA patients.
SUBJECTS AND METHODS
Subjects
Subjects were recruited by the consecutive sampling method after 
being given sufficient explanation and signing an informed consent 
form. They were then divided into two groups: RA patients and normal 
controls [9]. This study was approved by the Health Research Ethics 
Committee of the Dr. Hasan Sadikin Hospital, Indonesia.
The inclusion criteria are [9]:
a. RA patients of the Rheumatology Clinic at a Government Hospital in 
Bandung, Indonesia
b. RA patients who met at least four of the clinical criteria from the 
2010 RA classification criteria [10], based on examination by a 
rheumatologist without serology examination
c. RA patients willing to participate in this study and who signed an 
informed consent form
d. Patients over 18 years of age.
The exclusion criteria are [9]:
a. Patients who are uncooperative
b. Patients with a history of drug abuse including alcoholism
c. Patients with any other major medical disorder, including diabetes 
mellitus, hypertension, chronic obstructive pulmonary disease, acute 
or chronic liver disease, acute or chronic kidney disease, tuberculosis, 
and systemic lupus erythematosus.
All patients were interviewed regarding their age, disease duration, 
how many joints had definite clinical synovitis (swelling), symmetrical 
arthritis, pain duration in the morning, drug therapy, medical treatment 
undergone to reduce the pain such as surgery, and genealogy [9].
Methods
Serum preparation
Blood samples were collected from patients between March and May 
2016; samples were taken from a peripheral vein and placed in a tube 
without ethylenediaminetetraacetic acid. The samples were allowed 
to stand for 30 minutes to form a coagulant and then centrifuged at 
3000 rpm for 15 minutes. The serum was separated from the sediment 
and stored at −80°C.
Determination of serum calcium level
Serum calcium levels were measured using a modified complexometric 
method with a murexide reagent [11]. A total of 0.2 mL of serum or 
calcium standard solution was added to 0.8 mL of distilled water and 
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0.5 mL of murexide reagent and was thoroughly mixed. The mixture 
was allowed to stand for 5 minutes at room temperature to allow gas 
bubbles to rise and was then measured within the next 10 minutes 
using a spectrophotometer at 510 nm. The zero absorbance was set 
using distilled water as the blank solution.
Preparation of murexide reagent
About 4 mg of murexide (ammonium purpurate) was dissolved in 
0.5 mL distilled water. 1.5 mL 3.75 N potassium hydroxide and 5.0 mL 
distilled water were then added and thoroughly mixed.
Preparation of calcium standard solution: 0.2497 g of calcium carbonate 
was dissolved in 0.5 mL concentrated hydrochloric acid and was diluted 
to 100 mL with distilled water. The final concentration was 1 mg/mL.
Determination of serum COMP levels
Serum COMP levels were determined using the procedure described 
in The Human COMP/TSP5 enzyme-linked immunosorbent assay Pair 
Set (SEK10173) purchased from Sino Biological Inc. (USA). The method 
utilizes a monoclonal antibody specific for COMP/TSP5 coated on a 
96-well plate. Standards and samples were added to the wells, and any 
COMP/TSP5 present bonded with the immobilized antibody. The wells 
were washed and a biotinylated rabbit anti-COMP polyclonal antibody 
was then added, producing an antibody-antigen-antibody “sandwich.” 
Streptavidin-horseradish peroxidase and tetramethylbenzidine 
substrate solutions were then loaded to produce color, and the 
absorbance levels were measured using a spectrophotometer at 
450 nm.
Statistical analysis
The correlation between serum calcium levels and serum COMP levels 
was analyzed using the R software.
RESULTS
There were 30 RA patients who met the inclusion criteria with a mean 
age of 43.77±2.04 years old (range 20-64 years) for RA patients and 
41.23±2.46 years old (range 21-60 years) for normal controls (Fig. 1).
Regarding the condition of the patients, the interview data showed 
that the shortest disease duration was 3 months and the longest 
was 204 months. The most common disease duration for RA was 
1-12 months (Fig. 2) with an average of 56.13±49.24 months. In 
addition to a wide range of disease duration, the data also showed that 
the conditions of the patients varied. Most of the RA patients (80%) 
experienced joint pains for a minimum of 3-9 months before undergoing 
a medical checkup, while 16.67% of the patients had bone deformities 
due to the lack of early treatment. Furthermore, all patients felt pain 
in the small joints of the hands, wrists, elbows, knees, and ankles, in 
accordance with the common symptoms of RA [10], although joint 
stiffness was worse in the morning and evening than during the day. 
Finally, the interview data showed that 16.67% of the patients suffered 
hand deformities that reduced their grip strength and complicated their 
daily activities; 86.67% of the patients who experienced knee pain also 
experienced difficulties in walking for long periods, which interfered 
with their daily activities.
The results show that the serum calcium level was 82.24±44.82 mg/mL 
in RA patients and 99.04±60.56 mg/mL in the normal controls. At 
the same time, the serum COMP level was 843.80±35.79 ng/ml in RA 
patients and 830.00±48.92 ng/ml in the normal controls. Statistical 
analysis shows that there is no correlation between serum calcium level 
and serum COMP level in RA patients (p=0.967 and rho=0.006).
DISCUSSIONS
There were a total of 80 RA patients registered at the hospital between 
March and May 2016, but only 30 met the inclusion criteria: 26 were 
women (86.67%) and four were men (13.33%). This result is consistent 
with literature which states that the incidence of RA in women is seven 
times higher than in men, i.e. 87.43% [12] and 79.60% [13]. This is due 
to the effect of hormones, especially estrogen which affects autoimmune 
diseases such as RA, causing a higher RA incidence in women [14,15]. 
Estrogen plays a role in maturation of growing bone and prevention of 
bone loss. At the age above 30 years, female estrogen tends to decrease, 
which makes estrogen deficiency and triggers an imbalance of bone 
remodeling activity [16].
The results also show that the highest RA incidence was among patients 
50-59 years of age (Fig. 1). This is consistent with our previous study 
conducted at the same hospital between December 2014 and January 
2015 (n=24) [9]. Furthermore, the interview data show that the patients 
visited a doctor only after abnormal symptoms in the body. Their strenuous 
activities caused severe pain; and to cope with the pain, they consumed 
analgesics such as paracetamol or diclofenac sodium. This shows a lack of 
awareness of RA symptoms among the general public. Many Indonesians 
consider RA as a disease only the elderly suffer, so there is a lack of 
awareness regarding the health monitoring of joint pains among people 
under 50 years old. However, in our previous study, patients with higher 
educational levels showed a higher awareness of health monitoring [9,17].
Determination of the serum calcium level showed that it was lower 
in RA patients than in the normal controls, a result consistent with 
literature [18]. Calcium absorption in RA is reduced due to a primary 
malabsorptive process, but the mechanism is still unknown. One 
possibility is that an alteration in the oxidative metabolism leads to a 
disruption in the intracellular ionic environment and altered calcium 
levels [19]. This decreased calcium level in RA patients is an integral 
feature of RA [18]. However, some authors suggest that hypocalcemia is 
the result of the drugs used in RA treatment and may not be due to the 
disease itself [19]. Glucocorticoid therapy which given to RA patients 
can lead to bone loss. Glucocorticoids inhibit the calcium resorption in 
the renal tubules and calcium absorption in the gut through Vitamin 
Fig. 1: Distribution of patients according to age groups (n=30)
Fig. 2: Distribution of patients according to disease duration 
(n=30)
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D-dependent mechanisms, decrease trans-cellular active calcium 
transport and normal calcium absorption by brush-border membrane 
vesicles, and reduce the synthesis of calcium-binding protein [20,21].
Regarding the serum COMP levels, they were found to be slightly higher 
in RA patients compared to the normal controls, but the difference is 
not statistically significant. These was due to RA patient compliance in 
taking prescribed medication to maintain the patient’s quality of life and 
stabilize disease activity [22]. As serum COMP levels are higher in the 
early stages of RA, they are used to determine the severity and diagnosis 
of RA [23]. All of the patients with RA in this study were prescribed 
disease modifying antirheumatic drugs (DMARDs), nonsteroidal anti-
inflammatory drugs, and analgesics, which may affect the serum COMP 
levels. One such DMARD, methotrexate (MTX), modifies the development 
of joint damage, leading to a decreased COMP level along with improved 
joint conditions. MTX is proven to modify the progression of joint damage 
so that decreased the COMP levels with improving joint conditions [23]. 
There were 66.68% patients who were only prescribed MTX, while 
33.32% of the patients were prescribed MTX in combination with 
chloroquine, sulfasalazine, Cyclosporin, or azathioprine. Most patients 
(90%) were also prescribed methyl prednisolone, calcium, and folic acid 
to reduce the MTX side effects [22]. Finally, only 33.33% of the patients 
were given analgesics, (paracetamol, ibuprofen, diclofenac sodium, and 
aspirin). All patients showed good compliance regarding taking the 
medicines (otherwise they felt pain), which resulted in a not-significantly 
different COMP level between RA patients and the normal control. 
These results are consistent with our previous study in Puwarkarta, 
Indonesia [17]. The goal of appropriate and routine therapy is to maintain 
the quality of life of the patient and to stabilize disease activity.
Finally, statistical analysis showed that there is no correlation 
between the serum calcium level and serum COMP level (Fig. 3). This 
suggests patient compliance in drug consumption as MTX, which is an 
immunosuppressant, may suppress the progression of RA, resulting in 
low serum calcium and COMP levels in RA patients.
CONCLUSION
There is no correlation between serum calcium levels and serum COMP 
levels in RA patients (p=0.967 and rho=0.006). Further studies are 
required regarding the correlation of serum calcium and COMP levels in 
RA patients who have not been prescribed and are not currently taking 
any other medicine.
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Fig. 3: Distribution of serum calcium level to serum cartilage 
oligomeric matrix protein level (n=30)
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